Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.66 USD
Change Today +0.05 / 0.34%
Volume 168.7K
OMER On Other Exchanges
As of 8:10 PM 11/24/15 All times are local (Market data is delayed by at least 15 minutes).

omeros corp (OMER) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/18/15 - $30.23
52 Week Low
09/29/15 - $10.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for OMEROS CORP (OMER)

omeros corp (OMER) Related Bloomberg News

View More Bloomberg News

omeros corp (OMER) Related Businessweek News

No Related Businessweek News Found

omeros corp (OMER) Details

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery. The company’s clinical products include OMS721 that is in Phase II clinical trials for the treatment of various complement-mediated disorders, including complement-mediated thrombotic microangiopathies; OMS824, which is in Phase II clinical trials for the treatment of CNS disorders comprising schizophrenia and Huntington's disease; and OMS103 that has completed Phase III clinical trials for use during arthroscopic procedures, such as partial meniscectomy surgery. Its clinical programs also comprise OMS405, which is in Phase II clinical trials for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase I/II clinical trials for use during urological procedures, such as ureterscopy for removal of ureteral or renal stones. The company’s preclinical programs also comprise OMS527 for the treatment of addiction and compulsive disorders, as well as for movement disorders, such as Parkinson's disease; OMS616 for the control of blood loss during surgery, or resulting from trauma or other hyperfibrinolytic conditions; and OMS906 for the treatment of paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders. In addition, its preclinical products consist of GPR17 for the treatment of demyelinating disorders; G protein-coupled receptor platform for multiple disorders across therapeutic area; and antibody platform for the discovery of monoclonal antibodies. Omeros Corporation was incorporated in 1994 and is based in Seattle, Washington.

103 Employees
Last Reported Date: 03/16/15
Founded in 1994

omeros corp (OMER) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $684.1K
Principal Financial Officer, Chief Accounting...
Total Annual Compensation: $285.0K
Vice President of Patent, General Counsel and...
Total Annual Compensation: $352.6K
Compensation as of Fiscal Year 2014.

omeros corp (OMER) Key Developments

Omeros Corporation Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Omeros Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company reported total revenue of USD 3.259 million compared to USD 0.214 million a year ago. Loss from operations was USD 19.301 million compared to USD 17.132 million a year ago. Net loss was USD 19.921 million compared to USD 18.327 million a year ago. Basic and diluted net loss per share was USD 0.53 compared to USD 0.54 a year ago. For the nine months, the company reported total revenue of USD 6.834 million compared to USD 0.359 million a year ago. Loss from operations was USD 53.198 million compared to USD 50.033 million a year ago. Net loss was USD 55.27 million compared to USD 52.96 million a year ago. Basic and diluted net loss per share was USD 1.48 compared to USD 1.61 a year ago.

Omeros Corporation to Report Q3, 2015 Results on Nov 09, 2015

Omeros Corporation announced that they will report Q3, 2015 results at 5:00 PM, Eastern Standard Time on Nov 09, 2015

Omeros Corporation, Q3 2015 Earnings Call, Nov 09, 2015

Omeros Corporation, Q3 2015 Earnings Call, Nov 09, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OMER:US $14.66 USD +0.05

OMER Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $32.79 USD -1.08
Diplomat Pharmacy Inc $35.00 USD -0.23
Fagron €17.02 EUR -0.055
Imprimis Pharmaceuticals Inc $6.32 USD -0.11
Ocular Therapeutix Inc $8.74 USD +0.43
View Industry Companies

Industry Analysis


Industry Average

Valuation OMER Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 79.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 70.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OMEROS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at